Status:
UNKNOWN
Benefit of Lidocaine Perfusion in Cancer Related Visceral Pain Resistant to Morphinics
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Cancer
Pain
Eligibility:
All Genders
6-70 years
Phase:
PHASE3
Brief Summary
This study will evaluate the benefit of lidocaine perfusion in cancer related visceral pain resistant to morphinics. It is an efficacy study in adults and children and a randomized prospective study.
Eligibility Criteria
Inclusion
- Patients suffering from cancer of any type, at any stage, hospitalized at the Institut Gustave Roussy
- Aged from 6 to 14 years old (group A) and from 15 to 70 years old (adults)
- Presenting visceral pain due to neurotoxic chemotherapy, due to the tumoral mass or to peritoneal carcinosis
- Pain resistant to morphinic treatment
Exclusion
- Cardiac troubles, clinical cardiac insufficiency, or history of myocardial infarction (MI) of less than 3 months
- Neurological: non-controlled epilepsy, encephalopathy, or dementia
- Severe hepatic insufficiency
- Severe renal insufficiency
- Respiratory insufficiency
- Patients having surgery or in postoperative period
- Known deficit in G6PD, alanine exposure, or sulphamide treatment
- Porphyria
- Weight \> 80 kg
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00181012
Start Date
May 1 2005
Last Update
September 19 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institut Gustave-Roussy
Villejuif, France, 94800